

Makoto Miyara

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1793822/publications.pdf>

Version: 2024-02-01

54
papers

12,318
citations

126907

33
h-index

197818

49
g-index

66
all docs

66
docs citations

66
times ranked

19113
citing authors

#	ARTICLE	IF	CITATIONS
1	BNT162b2 vaccine-induced humoral and cellular responses against SARS-CoV-2 variants in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 575-583.	0.9	61
2	Pre-COVID-19 Immunity to Common Cold Human Coronaviruses Induces a Recall-Type IgG Response to SARS-CoV-2 Antigens Without Cross-Neutralisation. <i>Frontiers in Immunology</i> , 2022, 13, 790334.	4.8	10
3	The Polarity and Specificity of Antiviral T Lymphocyte Responses Determine Susceptibility to SARS-CoV-2 Infection in Patients with Cancer and Healthy Individuals. <i>Cancer Discovery</i> , 2022, 12, 958-983.	9.4	10
4	Airway replacement using stented aortic matrices: Long-term follow-up and results of the TRITON-01 study in 35 adult patients. <i>American Journal of Transplantation</i> , 2022, 22, 2961-2970.	4.7	15
5	Treg cell therapy: How cell heterogeneity can make the difference. <i>European Journal of Immunology</i> , 2021, 51, 39-55.	2.9	44
6	IgA dominates the early neutralizing antibody response to SARS-CoV-2. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	840
7	Prolonged SARS-CoV-2 RNA virus shedding and lymphopenia are hallmarks of COVID-19 in cancer patients with poor prognosis. <i>Cell Death and Differentiation</i> , 2021, 28, 3297-3315.	11.2	31
8	CD8+PD-L1+CXCR3+ polyfunctional T cell abundances are associated with survival in critical SARS-CoV-2â€“infected patients. <i>JCI Insight</i> , 2021, 6, .	5.0	16
9	Long-Term Follow-up Study after Lentiviral Hematopoietic Stem/Progenitor Cell Gene Therapy for Wiskott - Aldrich Syndrome. <i>Blood</i> , 2021, 138, 2934-2934.	1.4	1
10	Anti-MDA5 juvenile idiopathic inflammatory myopathy: a specific subgroup defined by differentially enhanced interferon-Î± signalling. <i>Rheumatology</i> , 2020, 59, 1927-1937.	1.9	26
11	Metabolic Optimisation of Regulatory T Cells in Transplantation. <i>Frontiers in Immunology</i> , 2020, 11, 2005.	4.8	10
12	Different phenotypes in dermatomyositis associated with anti-MDA5 antibody. <i>Neurology</i> , 2020, 95, e70-e78.	1.1	142
13	Regulatory T cells in solid organ transplantation. <i>Clinical and Translational Immunology</i> , 2020, 9, e01099.	3.8	53
14	Tissue Infiltrating LTiâ€™-Like Group 3 Innate Lymphoid Cells and T Follicular Helper Cells in Graves' and Hashimoto's Thyroiditis. <i>Frontiers in Immunology</i> , 2020, 11, 601.	4.8	13
15	Etiopathogenesis of ANCA-Associated Vasculitis. <i>Rare Diseases of the Immune System</i> , 2020, , 33-45.	0.1	0
16	Synergistic convergence of microbiota-specific systemic IgG and secretory IgA. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 1575-1585.e4.	2.9	86
17	High Serum VEGF Level in Erdheim-Chester Disease: Correlation with Cardiovascular Involvement and Response to Treatment. <i>Blood</i> , 2019, 134, 2324-2324.	1.4	2
18	Human ³FOXP</sup> T regulatory cell heterogeneity. <i>Clinical and Translational Immunology</i> , 2018, 7, e1005.	3.8	93

#	ARTICLE	IF	CITATIONS
19	Microbial ecology perturbation in human IgA deficiency. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	206
20	Detection in whole blood of autoantibodies for the diagnosis of connective tissue diseases in near patient testing condition. <i>PLoS ONE</i> , 2018, 13, e0202736.	2.5	12
21	Combination of IL-2, rapamycin, DNA methyltransferase and histone deacetylase inhibitors for the expansion of human regulatory T cells. <i>Oncotarget</i> , 2017, 8, 104733-104744.	1.8	20
22	Outcome and prognostic factors in a French cohort of patients with myositis-associated interstitial lung disease. <i>Rheumatology International</i> , 2016, 36, 1727-1735.	3.0	15
23	Relapsing polychondritis: A 2016 update on clinical features, diagnostic tools, treatment and biological drug use. <i>Best Practice and Research in Clinical Rheumatology</i> , 2016, 30, 316-333.	3.3	79
24	Suppressive activity of human regulatory T cells is maintained in the presence of TNF. <i>Nature Medicine</i> , 2016, 22, 16-17.	30.7	93
25	Ultraviolet light converts propranolol, a nonselective β -blocker and potential lupus-inducing drug, into a proinflammatory AhR ligand. <i>European Journal of Immunology</i> , 2015, 45, 3174-3187.	2.9	36
26	Thrombophilia Associated with Anti-DFS70 Autoantibodies. <i>PLoS ONE</i> , 2015, 10, e0138671.	2.5	17
27	Regulatory T Cell Responses to High-Dose Methylprednisolone in Active Systemic Lupus Erythematosus. <i>PLoS ONE</i> , 2015, 10, e0143689.	2.5	37
28	Sialyl Lewis x (CD15s) identifies highly differentiated and most suppressive FOXP3 ^{high} regulatory T cells in humans. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 7225-7230.	7.1	164
29	Chronic Malaria Revealed by a New Fluorescence Pattern on the Antinuclear Autoantibodies Test. <i>PLoS ONE</i> , 2014, 9, e88548.	2.5	13
30	Novel Clinical and Diagnostic Aspects of Antineutrophil Cytoplasmic Antibodies. <i>Journal of Immunology Research</i> , 2014, 2014, 1-12.	2.2	45
31	Analysis of Autoantibodies to 3-Hydroxy-3-methylglutaryl-coenzyme A Reductase Using Different Technologies. <i>Journal of Immunology Research</i> , 2014, 2014, 1-8.	2.2	41
32	TREG-cell therapies for autoimmune rheumatic diseases. <i>Nature Reviews Rheumatology</i> , 2014, 10, 543-551.	8.0	179
33	Hydroxychloroquine-Induced Pigmentation in Patients With Systemic Lupus Erythematosus. <i>JAMA Dermatology</i> , 2013, 149, 935.	4.1	91
34	Clinical Phenotypes of Patients with Anti-DFS70/LEDGF Antibodies in a Routine ANA Referral Cohort. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-8.	3.3	65
35	Transcriptional Blood Signatures Distinguish Pulmonary Tuberculosis, Pulmonary Sarcoidosis, Pneumonias and Lung Cancers. <i>PLoS ONE</i> , 2013, 8, e70630.	2.5	254
36	Regulatory T cells. , 2013, , 193-202.		1

#	ARTICLE	IF	CITATIONS
37	Activated and resting regulatory T cell exhaustion concurs with high levels of interleukin-22 expression in systemic sclerosis lesions. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1227-1234.	0.9	90
38	The extravascular compartment of the bone marrow: a niche for <i>Plasmodium falciparum</i> gametocyte maturation?. <i>Malaria Journal</i> , 2012, 11, 285.	2.3	90
39	Effector CD4 ⁺ CD45RA ^{hi} CD25 ^{bright} Foxp3 ^{bright} Regulatory T Cell (eTreg) Distribution Is Significantly Impaired in Chronic Myelomonocytic Leukemia (CMML) and Correlates with TET 2 Mutational Status.. <i>Blood</i> , 2012, 120, 2808-2808.	1.4	0
40	Human FoxP3 ⁺ CD4 ⁺ regulatory T cells: their knowns and unknowns. <i>Immunology and Cell Biology</i> , 2011, 89, 346-351.	2.3	168
41	Human FoxP3 ⁺ regulatory T cells in systemic autoimmune diseases. <i>Autoimmunity Reviews</i> , 2011, 10, 744-755.	5.8	298
42	Exhausted Cytotoxic Control of Epstein-Barr Virus in Human Lupus. <i>PLoS Pathogens</i> , 2011, 7, e1002328.	4.7	111
43	FOXP3 ⁺ regulatory T cells in the human immune system. <i>Nature Reviews Immunology</i> , 2010, 10, 490-500.	22.7	2,041
44	Human lupus, fewer Treg cells indeed: Comment on the article by Venigalla et al. <i>Arthritis and Rheumatism</i> , 2009, 60, 630-630.	6.7	5
45	Functional Delineation and Differentiation Dynamics of Human CD4 ⁺ T Cells Expressing the FoxP3 Transcription Factor. <i>Immunity</i> , 2009, 30, 899-911.	14.3	1,955
46	Therapeutic approaches to allergy and autoimmunity based on FoxP3 ⁺ regulatory T-cell activation and expansion. <i>Journal of Allergy and Clinical Immunology</i> , 2009, 123, 749-755.	2.9	89
47	FoxP3 ⁺ Regulatory T Cells Suppress Early Stages of Granuloma Formation but Have Little Impact on Sarcoidosis Lesions. <i>American Journal of Pathology</i> , 2009, 174, 497-508.	3.8	116
48	CTLA-4 Control over Foxp3 ⁺ Regulatory T Cell Function. <i>Science</i> , 2008, 322, 271-275.	12.6	2,490
49	Regulatory T Cells and the Control of Auto-Immunity: From day 3 Thymectomy to FoxP3 ⁺ Regulatory T Cells. , 2008, , 3-16.		1
50	Natural regulatory T cells: mechanisms of suppression. <i>Trends in Molecular Medicine</i> , 2007, 13, 108-116.	6.7	616
51	Regulatory T cells â€” a brief history and perspective. <i>European Journal of Immunology</i> , 2007, 37, S116-S123.	2.9	287
52	The immune paradox of sarcoidosis and regulatory T cells. <i>Journal of Experimental Medicine</i> , 2006, 203, 359-370.	8.5	392
53	Global Natural Regulatory T Cell Depletion in Active Systemic Lupus Erythematosus. <i>Journal of Immunology</i> , 2005, 175, 8392-8400.	0.8	416
54	Roles of CCR2 and CXCR3 in the T cell-mediated response occurring during lupus flares. <i>Arthritis and Rheumatism</i> , 2003, 48, 3487-3496.	6.7	49